Whitehawk Therapeutics, Inc. (WHWK)
NASDAQ: WHWK · Real-Time Price · USD
3.065
-0.015 (-0.49%)
Nov 11, 2026, 9:47 AM EST - Market open
Whitehawk Therapeutics Employees
Whitehawk Therapeutics had 37 employees as of September 30, 2026. The number of employees increased by 15 or 68.18% compared to the same quarter last year. That makes Whitehawk Therapeutics the 36,366th largest employer in the world and 4,988th in the United States.
Employees
37
Change (1Y)
15
Growth (1Y)
68.18%
Revenue / Employee
n/a
Profits / Employee
-$2,251,189
Market Cap
180.86M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2026 | 37 | 15 | 68.18% |
| Jun 30, 2026 | 32 | 11 | 52.38% |
| Mar 31, 2026 | 29 | 11 | 61.11% |
| Dec 31, 2025 | 23 | -17 | -42.50% |
| Sep 30, 2025 | 22 | -31 | -58.49% |
| Jun 30, 2025 | 21 | -49 | -70.00% |
| Mar 31, 2025 | 18 | -57 | -76.00% |
| Dec 31, 2024 | 40 | -49 | -55.06% |
| Sep 30, 2024 | 53 | -35 | -39.77% |
| Jun 30, 2024 | 70 | -19 | -21.35% |
| Mar 31, 2024 | 75 | -5 | -6.25% |
| Dec 31, 2023 | 89 | 10 | 12.66% |
| Sep 30, 2023 | 88 | 12 | 15.79% |
| Jun 30, 2023 | 89 | 22 | 32.84% |
| Mar 31, 2023 | 80 | 26 | 48.15% |
| Dec 31, 2022 | 79 | 40 | 102.56% |
| Sep 30, 2022 | 76 | 55 | 261.90% |
| Jun 30, 2022 | 67 | 57 | 570.00% |
| Mar 31, 2022 | 54 | 44 | 440.00% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| ProQR Therapeutics | 187 |
| Entrada Therapeutics | 152 |
| Invivyd | 122 |
| Keros Therapeutics | 92 |
| Upstream Bio | 75 |
| Compugen | 75 |
| Alpha Cognition | 71 |
| InflaRx | 65 |
WHWK News
- 2 days ago - Whitehawk Therapeutics reports Q3 EPS (23c), consensus (24c) - TheFly
- 2 days ago - Whitehawk Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights - PRNewsWire
- 2 days ago - Whitehawk Therapeutics Earnings release: Q3 2026 - Filings
- 2 days ago - Whitehawk Therapeutics Quarterly report: Q3 2026 - Filings
- 5 weeks ago - Whitehawk Therapeutics presents real-world analyses of MUC16 in ovarian cancer - TheFly
- 5 weeks ago - Whitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 as a Durable ADC Target in Ovarian Cancer at IGCS 2026 - PRNewsWire
- 5 weeks ago - Whitehawk Therapeutics initiated with a Buy at Stifel - TheFly
- 1 month ago - Whitehawk Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts